|
1
|
Koshy M, Villano JL, Dolecek TA, Howard A,
Mahmood U, Chmura SJ, Weichselbaum RR and McCarthy BJ: Improved
survival time trends for glioblastoma using the SEER 17
population-based registries. J Neurooncol. 107:207–212. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stevens MF, Hickman JA, Stone R, Gibson
NW, Baig GU, Lunt E and Newton CG: Antitumor imidazotetrazines. 1.
Synthesis and chemistry of
8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3, 5-tetrazin-4(3
H)-one, a novel broad-spectrum antitumor agent. J Med Chem.
27:196–201. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Agarwala SS and Kirkwood JM: Temozolomide
a novel alkylating agent with activity in the central nervous
system, may improve the treatment of advanced metastatic melanoma.
Oncologist. 5:144–151. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hegi ME, Diseren AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 325:997–1003. 2005. View Article : Google Scholar
|
|
5
|
Kanzawa T, Germano IM, Komata T, Ito H,
Kondo Y and Kondo S: Role of autophagy in temozolomide-induced
cytotoxicity for malignant glioma cells. Cell Death Differ.
11:448–457. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Natsumeda M, Aoki H, Miyahara H, Yajima N,
Uzuka T, Toyoshima Y, Kakita A, Takahashi H and Fujii Y: Induction
of autophagy in temozolomide treated malignant gliomas.
Neuropathology. 31:486–493. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang Z and Klionsky DJ: Eaten alive: A
history of macroautophagy. Nat Cell Biol. 12:814–822. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mizushima N, Yoshimorim T and Levine B:
Methods in mammalian autophagy research. Cell. 140:313–326. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fujita N, Hayashi-Nishino M, Fukumoto H,
Omori H, Yamamoto A, Noda T and Yoshimori T: An Atg4B mutant
hampers the lipidation of LC3 paralogues and causes defects in
autophagosome closure. Mol Biol Cell. 19:4651–4659. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yoon YH, Cho KS, Hwang JJ, Lee SJ, Choi JA
and Koh JY: Induction of lysosomal dilatation, arrested autophagy
and cell death by chloroquine in cultured ARPE-19 cells. Invest
Ophthalmol Vis Sci. 51:6030–6037. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng Y, Ren X, Hait WN and Yang JM:
Therapeutic targeting of autophagy in disease: Biology and
pharmacology. Pharmacol Rev. 65:1162–1197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sinha S and Levine B: The autophagy
effector Beclin 1: A novel BH3-only protein. Oncogene. 27 Suppl
1:S137–S148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wei Y, Zou Z, Becker N, Anderson M,
Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, et
al: EGFR-mediated Beclin 1 phosphorylation in autophagy
suppression, tumor progression, and tumor chemoresistance. Cell.
154:1269–1284. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Okamoto I, Kenyon LC, Emlet DR, Mori T,
Sasaki J, Hirosako S, Ichikawa Y, Kishi H, Godwin AK, Yoshioka M,
et al: Expression of constitutively activated EGFRvIII in non-small
cell lung cancer. Cancer Sci. 94:50–56. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gan HK, Kaye AH and Luwor RB: The EGFRvIII
variant in glioblastoma multiforme. J Clin Neurosci. 16:748–754.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ishii N, Maier D, Merlo A, Tada M,
Sawamura Y, Diserens AC and Van Meir EG: Frequent co-alterations of
TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human
glioma cell lines. Brain Pathol. 9:469–479. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schäfer A, Teufel J, Ringel F, Bettstetter
M, Hoepner I, Rasper M, Gempt J, Koeritzer J, Schmidt-Graf F, Meyer
B, et al: Aldehyde dehydrogenase 1A1-a new mediator of resistance
to temozolomide in glioblastoma. Neuro Oncol. 14:1452–1464. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Berezowska S, Diermeier-Daucher S,
Brockhoff G, Busch R, Duyster J, Grosu AL and Schlegel J: Effect of
additional inhibition of human epidermal growth factor receptor 2
with the bispecific tyrosine kinase inhibitor AEE788 on the
resistance to specific EGFR inhibition in glioma cells. Int J Mol
Med. 26:713–721. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ciechomska IA, Przanowski P, Jackl J,
Wojtas B and Kaminska B: BIX01294, an inhibitor of histone
methyltransferase, induces autophagy-dependent differentiation of
glioma stem-like cells. Sci Rep. 6:387232016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rappl A, Piontek G and Schlegel J:
EGFR-dependent migration of glial cells is mediated by
reorganisation of N-cadherin. J Cell Sci. 121:4089–4097. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bobola MS, Tseng SH, Blank A, Berger MS
and Silber JR: Role of O6-methylguanine-DNA methyltransferase in
resistance of human brain tumor cell lines to the clinically
relevant methylating agents temozolomide and streptozotocin. Clin
Cancer Res. 2:735–741. 1996.PubMed/NCBI
|
|
22
|
Klionsky DJ, Abdelmohsen K, Abe A, Abedin
MJ, Abeliovich H, Arozena A Acevedo, Adachi H, Adams CM, Adams PD,
Adeli K, et al: Guidelines for the use and interpretation of assays
for monitoring autophagy (III edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weller M, Cloughesy T, Perry J and Wick W:
Standards of care for treatment of recurrent glioblastoma-are we
there yet? Neuro Oncol. 15:4–27. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Soeda1 A, Hara A, Kunisada T, Yoshimura S,
Iwama1 T and Park D: The evidence of glioblastoma heterogeneity.
Sci Rep. 5:79792015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fan C, Wang W, Zhao B, Zhang S and Miao J:
Chloroquine inhibits cell growth and induces cell death in A549
lung cancer cells. Bioorg Med Chem. 14:3218–3222. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Briceño E, Calderon A and Sotelo J:
Institutional experience with chloroquine as an adjuvant to the
therapy for glioblastoma multiforme. Surg Neurol. 67:388–391. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Seidel S, Garvalov BK and Acker T:
Isolation and culture of primary glioblastoma cells from human
tumor specimens. Methods Mol Biol. 1235:263–275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thon N, Kreth S and Kreth FW: Personalized
treatment strategies in glioblastoma: MGMT promoter methylation
status. Onco Targets Ther. 6:1363–1372. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wick W, Platten M and Weller M: New
(alternative) temozolomide regimens for the treatment of glioma.
Neuro Oncol. 11:69–79. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bleeker FE, Molenaar RJ and Leenstra S:
Recent advances in the molecular understanding of glioblastomas. J
Neurooncol. 108:11–27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eskilsson E, Røsland G, Talasila K, Jahedi
R, Leiss L, Saed H, Keunen O, Foerster S, Euskirchen P, Hossain J,
et al: Distinct EGFR signaling in Glioblastoma: Wild-type EGFR
promotes invasion while EGFRvIII drives prototypical SFK c-SRC
activation to foster angiogenesis. Neuro Oncol. 16 Suppl 5:v32014.
View Article : Google Scholar
|
|
32
|
Li L, Puliyappadamba VT, Chakraborty S,
Rehman A, Vemireddy V, Saha D, Souza RF, Hatanpaa KJ, Koduru P,
Burma S, et al: EGFR wild type antagonizes EGFRvIII-mediated
activation of Met in glioblastomas. Oncogene. 34:129–134. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shinojima N, Tada K, Shiraishi S, Kamiryo
T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, et
al: Prognostic value of epidermal growth factor receptor in
patients with glioblastoma multiforme. Cancer Res. 63:6962–6970.
2003.PubMed/NCBI
|
|
34
|
Montano N, Cenci T, Martini M,
D'Alessandris QG, Pelacchi F, Ricci-Vitiani L, Maira G, de Maria R,
Larocca LM and Pallini R: Expression of EGFRvIII in glioblastoma:
Prognostic significance revisited. Neoplasia. 12:1113–1121. 2011.
View Article : Google Scholar
|
|
35
|
Padfield E, Ellis HP and Kurian KM:
Current therapeutic advances targeting EGFR and EGFRvIII in
glioblastoma. Front Oncol. 5:52015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu Y and Shah K: Multiple lesions in
receptor tyrosine kinase pathway determine glioblastoma response to
pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor
PF-05212384. Cancer Biol Ther. 15:815–822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tan X, Thapa N, Sun Y and Anderson RA: A
kinase-independent role for EGF receptor in autophagy initiation.
Cell. 160:145–160. 2015. View Article : Google Scholar : PubMed/NCBI
|
